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Background: Factors associated with HCV incidence among young Aboriginal people in Canada are still not well
understood. We sought to estimate time to HCV infection and the relative hazard of risk factors associated HCV
infection among young Aboriginal people who use injection drugs in two Canadian cities.
Methods: The Cedar Project is a prospective cohort study involving young Aboriginal people in Vancouver and
Prince George, British Columbia, who use illicit drugs. Participants’ venous blood samples were drawn and tested
for HCV antibodies. Analysis was restricted to participants who use used injection drugs at enrolment or any of
follow up visit. Cox proportional hazards regression was used to identify independent predictors of time to HCV
seroconversion.
Results: In total, 45 out of 148 participants seroconverted over the study period. Incidence of HCV infection was
26.3 per 100 person-years (95% Confidence Interval [CI]: 16.3, 46.1) among participants who reported using injection
drugs for two years or less, 14.4 per 100 person-years (95% CI: 7.7, 28.9) among participants who had been using
injection drugs for between two and five years, and 5.1 per 100 person-years (95% CI: 2.6,10.9) among participants
who had been using injection drugs for over five years. Independent associations with HCV seroconversion were
involvement in sex work in the last six months (Adjusted Hazard Ratio (AHR): 1.59; 95% CI: 1.05, 2.42) compared to
no involvement, having been using injection drugs for less than two years (AHR: 4.14; 95% CI: 1.91, 8.94) and for
between two and five years (AHR: 2.12; 95%CI: 0.94, 4.77) compared to over five years, daily cocaine injection in the
last six months (AHR: 2.47; 95% CI: 1.51, 4.05) compared to less than daily, and sharing intravenous needles in the
last six months (AHR: 2.56; 95% CI: 1.47, 4.49) compared to not sharing.
Conclusions: This study contributes to the limited body of research addressing HCV infection among Aboriginal
people in Canada. The HCV incidence rate among Cedar Project participants who were new initiates of injection
drug use underscores an urgent need for HCV and injection prevention and safety strategies aimed at supporting
young people surviving injection drug use and sex work in both cities. Young people must be afforded the
opportunity to provide leadership and input in the development of prevention programming.* Correspondence: spittal@sm.hivnet.ubc.ca
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Increasing levels of HCV infection among young Abori-
ginal people are distressing for many Aboriginal com-
munities and service providers, not only in small and
large urban centres but also in rural settings where
healthcare resources are limited [1,2]. This situation is
exacerbated by the fact that the major consequences of
HCV infection, including cirrhosis of the liver and hepa-
tocellular cancer do not develop for many decades after
initial infection [3]. Available data have demonstrated
that Aboriginal people are not only disproportionately
represented among HCV infected people in Canada but
also underrepresented in community based treatment
programs [4]. In British Columbia, it is estimated that
incidence for HCV infection is twice as high among
Aboriginal people compared to non-Aboriginal people
[5] and that over half the population of Aboriginal
people living with HIV are HCV co-infected, making the
treatment challenges associated with being HCV and
HIV co-infected far more complex [6]. Unfortunately,
national HCV surveillance data for indigenous people in
Canada is considered to be very limited largely because
of under reporting and lack of consistent documentation
of ethnic status between provinces [7,8]. Despite these
limitations the Public Health Agency of Canada has
identified that HCV incidence among Aboriginal people
in Canada is 5 to 6 fold higher than among non-
Aboriginal people [8]. The majority of these new infec-
tions can be attributed to injection drug use and the
sharing of contaminated injection equipment [7,9].
There is also increasing evidence that HCV is dispro-
portionately impacting Aboriginal young people. As Roy
et al [10]. have suggested, recent onset of injection is a
particularly vulnerable time for young people and the
risk for HCV seroconversion is extremely high. In a pre-
vious study, we demonstrated that approximately 11% of
our participants will transition to injection drug use per
year; a rate that is twice as high as that found in a simi-
lar longitudinal investigation conducted in Montreal
[11,12]. A number of prospective studies in Canada have
examined HCV infection among people who use injec-
tion drugs. However, most have been limited by the fact
that they are older cohorts and characterized by high
HCV prevalence and small numbers of Aboriginal
people, making it difficult to assess risk factors relevant
for Aboriginal specific programming.
Concerns over the paucity of available data and the
potential for explosive HIV and HCV epidemics among
Aboriginal young people in other areas of the province
similar to those reported in the mid-1990s in Vancou-
ver’s downtown eastside prompted the initiation of a
two city cohort study to address the specific HIV and
HCV related vulnerabilities of Aboriginal young people
who use illicit drugs. To our knowledge, this is the onlylongitudinal study of young and ‘at risk’ indigenous peo-
ples of its kind in North America. Follow-up of the co-
hort allowed us to estimate the incidence of HCV
infection among young people enrolled in the Cedar
Project and identify risk factors associated with serocon-
version among study participants.Methods
The Cedar Project is an ongoing prospective study of
young Aboriginal people who use drugs in Vancouver
and Prince George, Canada. Previous studies have
described the methodology of the Cedar study in detail
including the proportion of Aboriginal young people liv-
ing in BC, participant recruitment and questionnaire de-
sign [13]. Briefly, young people who self identified as
Aboriginal people were considered to be the descendants
of the First Nation Peoples of North America and in-
clude Métis, Aboriginal, First Nations, Inuit and status
and non-status Indians. Participants living primarily in
the downtown areas of both cities were recruited
through referral by health care providers, community
outreach and word of mouth. Eligibility criteria for
study entry included age 14 to 30 years and to have
smoked or injected illicit drugs, aside from marijuana,
in the month prior to enrolment. Saliva screens (Oral-
screen, Avitar Onsite Diagnostics) were used to con-
firm drug use. All participants met with one First
Nations study coordinator who explained procedures,
sought informed consent and confirmed study eligibil-
ity. At enrolment, participants completed a detailed
interviewer-administered questionnaire to elicit infor-
mation on socio-demographic characteristics, non-
injection and injection drug use, injection practices,
sexual vulnerability and service utilization. Participants
were followed-up every six months for subsequent
interviews. Venous blood samples were drawn and
tested for HIV and HCV-antibodies at each visit, and
each participant had private interviews including pre-
and post-test counselling with trained nurses. Partici-
pants were requested but not required to return for
their HIV/HCV serostatus test results and given a
twenty dollar stipend at each study visit.
Since they were established in 2010, we have enthusi-
astically embraced the Tri-Council Policy Statement:
Ethical Conduct for Research Involving Humans, with
particular attention to Section 9, which pertains to re-
search involving Aboriginal participants. Our First
Nations collaborators and investigators were involved
in the conception, design and interpretation of this
study and approved this manuscript for publication.
The University of British Columbia/Providence Health
Care Research Ethics Board has also approved the
study.
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The main outcome of interest in this study was HCV
antibody seroconversion among participants who
reported injection drug use between January 2003 and
January 2009. We used algorithms for HCV serologic
testing similar to those used in other studies conducted
in this region [14]. In brief, AxSYM HCV version 3.0
(Abbott Laboratories, Chicago, Ill.) was used to screen
all plasma samples. Negative samples did not undergo
further testing. All positive samples underwent further
testing with the recombinant Ortho HCV 3.0 ELISA test
system (Ortho Clinical Diagnostic Inc., Rochester, NY).
Samples that tested positive with both assays were classi-
fied as positive. Samples that tested positive by the
AxSYM HCV test and negative by the Ortho HCV test
were classified as negative. Because of the known associ-
ation of the HCV virus with parenteral drug use, HCV
incidence rates were estimated by three categories using
the variable time since initiation of injection drug use.
The variable was coded for relatively equal distribution
between participants who had been injecting for <2 years
(n = 40), those who had been injecting for 2–5 years
(n = 40) and those who had been injecting for over
5 years (n = 66).
The following fixed dichotomous baseline covariates
were used in the analysis: interviewed in Vancouver; sex;
identifying as gay, lesbian, bisexual or two-spirited; hav-
ing at least one parent who had attended residential
school; ever having been placed into foster care; ever
having attempted suicide; and ever having experienced
sexual abuse. Sexual abuse was defined as any type of
sexual activity into which participants had either been
forced or coerced (including childhood sexual abuse,
molestation, rape and sexual assault). Nonfixed (oc-
curred in the past six months) covariates included age,
being in a relationship, having lived on the streets for a
period of three nights or more, having been in jail or
prison overnight or longer, having been denied shelter
because of drug use, having been involved in sex work,
having any sexually transmitted infection, having been
incarcerated overnight or longer, presence of antibodies
to HIV, time since initiation of injection drug use, daily
vs. less than daily use of injection cocaine, daily vs. less
than daily use of injection opioids (including heroin,
morphine, methadone, dilaudid or talwin and speedballs
(combination of cocaine and heroin)), daily vs. less than
daily use of injection methamphetamine, rig sharing,
having overdosed, and inconsistent use of condoms dur-
ing insertive sex (vaginal, anal) with casual, regular or
client partners. Sexual assault was defined as having
experienced sexual violence in the past six months. Sex
work was defined as receiving money, shelter, food or
drugs in exchange for sex. Sexual relationships that
lasted less than three months were defined as casualsexual partners, more than three months were defined
as regular partners, and clients were relationships where
sex was exchanged for money, food, drugs or shelter.
The Cedar Project cohort includes 605 participants in
total, however this study included only participants who
reported injection drug use, were HCV negative at base-
line, reported injection drug use and who returned for at
least one of eight follow-up interviews up to December
2008 (n = 148). HCV incidence was calculated as inci-
dence density. HCV incidence was calculated separately
for groups including participants from Vancouver and
Prince George, all participants together, and for partici-
pants who had been using injection drugs for less than
two years, those who had been using injection drugs for
between two and five years, and those who had been
using injection drugs for five or more years. The date of
seroconversion was estimated using the midpoint be-
tween the last negative and the first positive antibody
test result. Cumulative incidence rates of HCV infection
were calculated using Kaplan Meier methods. In these
analyses time 0 was defined as the date of enrolment.
We assessed the proportionality assumptions using the
log minus log curve for the fixed covariates used in the
model and observed no violations of assumptions. Parti-
cipants who consistently remained HCV seronegative
were considered to be right censored at the time of their
most recent test result. Annual rates of HCV serocon-
version were calculated with actuarial methods per 100
person years. Relative risks and 95% confidence intervals
were obtained for risk factors of interest.
Cox proportional hazards regression were used to
examine the independent effect of both fixed and time-
dependent covariates on time to HCV seroconversion.
Adjusted and unadjusted time dependent Cox regression
models were used to identify risk associations with HCV
seroconversion with Hazard Ratios and 95% confidence
intervals were obtained for risk factors of interest. Back-
ward stepwise Cox proportional hazards model included
all variables that were statistically associated with HCV
seroconversion at a p <0.10 significance level in un-
adjusted analyses. The adjusted model controlled for the
significant covariates to determine which of those risk
factors are independently associated with HCV serocon-
version. All reported p-values are two-sided.
Overall, 605 (305 in Vancouver and 300 in Prince
George) young Aboriginal people were recruited and
screened for enrolment in the Cedar Project study.
Among them, 292 (48%) were women and the mean age
was 23.5 years (Standard Deviation (SD): 4.0). A total of
335 (55.4%) participants reported that they had used in-
jection drugs before enrolment, and 42 (6.9%) reported
that they had initiated injection drug use in the time after
enrolment. The mean age of first having injected drugs
was 20.2 years (SD: 4.6). Among the 377 participants
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HCV seronegative at time of their baseline interview.
Out of 175 participants, 148 completed at least one
follow-up visit, yielding a follow-up rate of 85%. In total,
148 participants were therefore eligible for inclusion in
the HCV incidence analysis.
Results
In total, 148 participants were eligible for inclusion in the
analysis. Descriptive baseline statistics are provided in
Table 1. The median age of participants at baseline was
23 years (standard deviation: 3.9), 53.4% were women
and 57.4% were located in Vancouver. In addition, 11.5%
identified as gay/lesbian/bisexual/transgender or two-
spirited, 52.1% reported that they had ever been sexu-
ally abused and 68.2% had ever been taken from their
biological parents into the child welfare system. In
total, these 148 participants contributed 338.6 person
years of observation over the study period. The mean
length of follow-up time was 2.6 years (SD: 1.6) for all
participants, 1.3 years (SD: 1.1) for those who became
HCV positive and 3.2 years (SD: 1.5) for those who
remained HCV negative. Table 2 demonstrates the inci-
dence of HCV among Cedar Project participants over-
all, and among those who reported using injection
drugs for 2 years or less, between 2-5 years and over 5
years. Overall, 45 participants seroconverted during the
observation period yielding an incidence density of 11.6
cases per 100 person years (95% Confidence Interval
(CI): 8.5%, 17.1%). Incidence of HCV infection was
higher in Prince George than in Vancouver (14.8 vs.
9.6 per 100 person years), but this difference was not
statistically significant (Log-rank test, p = 0.186). Inci-
dence of HCV infection was 26.3 per 100 person-years
(95% CI: 16.3, 46.1) among participants who reported
using injection drugs for two years or less, 14.4 per
100 person-years (95% CI, 7.7, 28.9) among participants
who had been using injection drugs for between two
and five years, and 5.1 per 100 person-years (95% CI:
2.6,10.9) among participants who had been in using in-
jection drugs for over five years.
Figure 1 demonstrates the survival estimates for time
to HCV seroconversion among participants who had
only been injecting for two years or less, those who had
been using injection drugs for between two and five
years, and those who had been injecting for over five
years. For those newest to injection drug use, the cumu-
lative HCV incidence increased sharply to approximately
38% within the first year of follow-up and was over 50%
by the third year of follow-up.
Results from unadjusted and adjusted Cox regression
analyses for factors associated with HCV incidence are
displayed in Table 1. In unadjusted analyses, risk for
HCV seroconversion was significantly associated withhaving been involved in sex work in the last six months
(Unadjusted Hazard Ratio (UHR): 1.79; 95% CI: 1.16,
2.53). Risk for seroconversion appeared to decline with
duration of injecting, as the hazard for HCV was signifi-
cantly higher for participants who reported having been
injecting drugs for less than two years (UHR: 4.57; 95%
CI: 2.91, 9.51), and for those who had been injecting for
between two and five years (UHR: 2.43; 95% CI: 1.09,
5.45) compared to those who had been injecting for five
or more years. HCV risk also appeared to rise with
increased frequency of injection, as participants who
reported daily cocaine injection in the last six months
(UHR: 3.94; 95% CI: 2.49, 6.24) and daily opioid injec-
tion in the last six months (UHR: 2.06; 95% CI: 1.43,
2.98) had significantly higher rates of HCV incidence
compared to participants who were injecting cocaine or
opioids less than daily. In addition, participants who
reported unsafe injection practices in the last six months
including sharing rigs (UHR: 3.35; 95% CI: 2.09, 5.39),
reusing one’s own rig (UHR: 2.17; 95% CI: 1.48, 3.19)
and having a difficult time finding new rigs (UHR: 2.16;
95% CI: 1.31, 3.57) had significantly higher risk for HCV
seroconversion.
In the adjusted backward stepwise Cox regression
model, independent associations with HCV seroconver-
sion among Cedar Project participants who used injec-
tion drugs were involvement in sex work in the last six
months (Adjusted Hazard Ratio (AHR): 1.59; 95% CI:
1.05, 2.42), having been using injection drugs for less
than two years (AHR: 4.14; 95% CI: 1.91, 8.94) and for
between two and five years (AHR: 2.12; 95%CI: 0.94-
4.77), daily cocaine injection in the last six months
(AHR: 2.47; 95% CI: 1.51, 4.05) and sharing rigs in the
last six months (AHR: 2.56; 95% CI: 1.47, 4.49).
Discussion
Our findings have illustrated that young Aboriginal
people are at very high risk of HCV infection early in
their injection careers. The declining risk with longer
durations of injection was not surprising. It is likely that
a form of survivorship bias is operative here. The ana-
lysis was based on those who were HCV negative at re-
cruitment, therefore highest risk individuals in the
longer-using groups would have seroconverted to HCV
prior to the study, leaving lower risk groups for inclusion
in this analysis. However, it is shocking that approxi-
mately 26% of participants became infected with HCV
within two years of initiating injection drug use in two
cities with established harm reduction programs. It is
clear from this observation that the timeframe in which
to provide access to meaningful preventative interven-
tions after these young people initiate injection drug use
is very short and that harm reduction programs must do
a better job of reaching them [11,15,16].
Table 1 Unadjusted and adjusted* backward stepwise Cox regression models for vulnerabilities associated with HCV
incidence among Cedar participants who used injection drugs (n = 148)
Variable Baseline^
n (%)
Unadjusted HR
(95% CI)
P value Adjusted HR
(95% CI)
P value
Location -
Prince George 63 (42.6) 1.48 (0.82, 2.66) 0.676
Vancouver 85 (57.4) 1.0 (Reference)
Sex
Female 79 (53.4) 1.43 (0.79, 2.60) -
Male 69 (46.6) 1.0 (Reference) 0.240
Age at enrolment 23.1** (3.9) 0.95 (0.87, 1.02) 0.161 - -
Sexual identity
Gay/bisexual/two-spirited 17 (11.5) 1.62 (0.72, 3.63) 0.242 - -
Straight 131 (88.5) 1.0 (Reference)
At least one parent in residential school - -
Yes 81 (54.7) 0.95 (0.53, 1.70) 0.850
No/unsure 67 (45.3) 1.0 (Reference)
Ever taken into foster care - -
Yes 101 (68.2) 1.29 (0.67, 2.51) 0.445
No 47 (31.8) 1.0 (reference)
Ever sexually abused -
Yes 76 (52.1) 1.66 (0.91, 3.04) 0.098 -
No/unsure 70 (47.9) 1.0 (reference)
Sexual assault last 6 months - -
Yes 3 (2) 1.19 (0.37, 3.85) 0.770
No 145 (98) 1.0 (reference)
Relationship status last 6 months - -
Single 115 (77.8) 0.96 (0.64, 1.45) 0.856
In a relationship 33 (22.2) 1.0 (Reference)
Ever on streets for >3 nights 0.845 - -
Yes 56 (38.1) 0.94 (0.52, 1.72)
No 91 (61.9) 1.0 (reference)
On street for > nights last 6 months -
Yes n/a 1.26 (0.83, 1.90) 0.275 -
No 1.0 (reference)
Ever been in jail prison
Yes 97 (66) 1.11 (0.59, 2.09) 0.742 - -
No 50 (34) 1.0 (reference)
Been in jail or prison last 6 months - -
Yes 38 (25.7) 1.25 (0.83, 1.89) 0.291
No 110 (74.3) 1.0 (reference)
Ever attempted suicide
Yes 66 (44.6) 0.67 (0.37, 1.23) 0.195 - -
No 82 (55.4) 1.0 (reference)
Number of lifetime sexual partners 0.530 - -
>20 70 (48.6) 1.21 (0.67, 2.18)
<20/refused 74 (51.4) 1.0 (reference)
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Table 1 Unadjusted and adjusted* backward stepwise Cox regression models for vulnerabilities associated with HCV
incidence among Cedar participants who used injection drugs (n = 148) (Continued)
Ever involved in sex work - -
Yes 67 (45.6) 1.63 (0.90, 2.96) 0.107
No 80 (54.4) 1.0 (reference)
Involved in sex work last 6 months
Yes 47 (31.8) 1.71 (1.16, 2.53) 0.007 1.59 (1.05, 2.42) 0.030
No 101 (68.2) 1.0 (reference) 1.0 (reference)
Condom use for insertive sex with regular partner last 6 months - -
Not always 62 (41.9) 0.82 (0.51, 1.34) 0.437
Always 86 (58.1) 1.0 (reference)
Condom use for insertive sex with causal partner last 6 months - -
Not always 28 (18.9) 0.60 (0.24, 1.48) 0.268
Always 120 (81.1) 1.0 (reference)
Condom use for insertive sex with clients last 6 months - -
Not always 6 (4.1) 1.96 (0.61, 6.36) 0.260
Always 142 (95.9) 1.0 (reference)
Ever had a STI
Yes 65 (43.9) 1.17 (0.65, 2.12) - -
No 83 (56.1) 1.0 (reference) 0.604
Had a STI last 6 months
Yes 16 (10.8) 0.94 (0.36, 2.50) 0.908 - -
No 132 (89.2) 1.0 (reference)
Ever overdose
Yes 48 (32.4) 0.76 (0.42, 1.40) 0.382 - -
No 100 (67.6) 1.0 (reference)
Overdose last 6 months
Yes 20 (13.5) 1.71 (0.82, 3.58) 0.152 - -
No 128 (86.5) 1.0 (reference)
Time since initiation of injection drug use1
< 2 years n/a 4.57 (2.19, 9.51) <0.001 4.14 (1.91, 8.94) <0.001
2-5 years 2.43 (1.09, 5.45) 0.031 2.12 (0.94, 4.77) 0.070
> 5 years 1.0 (reference) 1.0 (reference)
Frequency of injection cocaine last 6 months
Daily 16 (10.8) 3.94 (2.49, 6.24) <0.001 2.47 (1.51, 4.05) <0.001
< Daily/non-user 132 (89.2) 1.0 (reference) 1.0 (reference)
Frequency of injection methamphetamine last 6 months - -
Daily 4 (2.7) 1.79 (0.90, 3.57) 0.099
< Daily/non-user 144 (97.3) 1.0 (reference)
Frequency of injection opiates last 6 months - -
Daily 27 (18.2) 2.06 (1.43, 2.98) <0.001
< Daily/non-user 125 (81.7) 1.0 (reference)
Syringe sharing last 6 months
Yes 19 (12.8) 3.35 (2.09, 5.39) <0.001 2.56 (1.47, 4.49) 0.001
No 129 (87.2) 1.0 (reference) 1.0 (reference)
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Table 1 Unadjusted and adjusted* backward stepwise Cox regression models for vulnerabilities associated with HCV
incidence among Cedar participants who used injection drugs (n = 148) (Continued)
Reuse of own syringes last 6 months - -
Yes 13 (9.1) 2.17 (1.48, 3.19) <0.001
No 131 (90.9) 1.0 (reference)
Hard to find new syringes last 6 months - -
Yes 15 (10.1) 2.16 (1.31, 3.57) 0.003
No 133 (89.9) 1.0 (reference)
Need help injecting last 6 months - -
Yes 38 (25.7) 1.14 (0.61, 2.14) 0.687
No 110 (74.3) 1.0 (reference)
Accessed any alcohol or drug treatment program last 6 months - -
Yes 31 (21.1) 1.25 (0.81, 1.93) 0.317
No 116 (78.9) 1.0 (reference)
Unable to access drug treatment program - -
Yes 22 (15) 0.90 (0.48, 1.69) 0.741
No 125 (85) 1.0 (reference)
Currently in methadone treatment program - -
Yes 5 (3.4) 2.11 (0.83, 5.37) 0.117
No 143 (96.6) 1.0 (reference)
*All variables significant at the p≤ 0.10 level in unadjusted analysis were included in the adjusted backward stepwise Cox proportional hazards model.
HR Hazard Ratio.
^Responses with less than n = 148 participants reflect missing data.
**Mean age (standard deviation).
1For those who had seroconverted to HCV positive, variable was time to seroconversion; and those who were non-incident cases, variable measured time to last
follow up visit since initiation of injection.
n/a: not available.
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reported frequent drug injection and syringe sharing
over the study period had over twice the risk for HCV
infection. Poly-drug use was common in this group.
More than half of those who reported daily cocaine in-
jection also reported daily opiate injection (data not
shown). It is noteworthy that daily cocaine injection
remained associated with HCV infection in the multi-
variable model while daily opiate injection did not. This
is consistent with a previous study in Vancouver that
demonstrated acquisition of HIV among injection drug
users was directly related to frequent use of injectionTable 2 HCV incidence among Cedar Project participants wh
2–5 years and over 5 years
HCV incidence Incident cases Tot
yea
Overall 45
≤2 years since initiation of injection drug use 21
2-5 years since initiation of IDU 13
Over 5 years since initiation of IDU 11cocaine as opposed to opiates, particularly as a conse-
quence of ‘cocaine binges’ [17]. We find it very concern-
ing that despite scaling up harm reduction efforts, high
intensity injection cocaine and syringe sharing continues
to be exposing Cedar Project participants to high risk
for HCV infection in both the northern and southern
urban communities. Increased efforts must be made to
engage young people who are new to injection drug use
in harm reduction service provision, including injection
equipment, addiction treatment and HIV and HCV test-
ing services. Moreover, while early intervention with
young people who have recently transitioned to injectiono had been using injection drugs for less than 2 years,
al person
rs
Incidence density
(per 100 person years)
95% Confidence Interval
(per 100 person years)
387.9 11.6 8.5- 17.1
79.7 26.3 16.3-46.1
90.4 14.4 7.7-28.9
214.5 5.1 2.6-10.9
Figure 1 Kaplan Meier Curves of HCV incidence rates by length of time participants reported use of injection drugs (2 years or less,
2–5 years, and over 5 years).
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at prevention of injection drug use must also be priori-
tized. In both Vancouver and Prince George, the com-
plex interplay between the impact of colonization,
residential schools, racialized care, and generations of
mistrust of both provincial and federal authorities must
be acknowledged [18]. When designing new program-
ming service providers must be mindful of how the past
can shape the response to prevention initiatives [19] and
nurture flexible, trust-based relationships that seek to
build upon young Aboriginal people’s resiliency in the
face of intergenerational and lifetime traumas [20]. Any
efforts to alleviate the immense impact of drug related
harm but be inclusive of the perspectives of those young
people who have learned how to ‘remain safe’ and have
avoided infection via injection drug use [21]. Further-
more, young people must be afforded the opportunity to
provide leadership in programme design intended to re-
flect their needs.
An independent association was also found in this
study between recent involvement in sex work and HCV
seroconversion. These results provide evidence that the
risk for HCV among participants who had been involved
in sex work was 59% higher compared to those who had
not been involved in sex work. Recent studies conducted
in British Columbia’s lower mainland have demonstrated
that impoverished Aboriginal women involved in sex
work and concomitant illicit drug use continue to be
exposed to alarming levels of drug related harm, infec-
tious disease and violent predation [22-24]. Sadly, these
findings are consistent with other settings internationallywhere women exchanging sex for basic needs including
drug dependence, are exposed to alarming levels of vio-
lence and infectious disease [25]. These data indicate the
critical need for scaling up services aimed at reducing
drug or sex related harm for young Aboriginal women,
particularly in Northern and remote communities. It is
important to highlight that many young Aboriginal
women involved in sex work are intimately involved
with men who are usually older and who also use injec-
tion drugs [23,26]. Indeed research has demonstrated
that for women who rely on their intimate partners for
drug acquisition, preparation and injection, the distribu-
tion of power and control in intimate relationships often
lies with drug injecting men who control the money and
the drugs [27,28]. Combined, these factors lead to a
greater likelihood of unsafe sex and the female partner
more likely coming “second on the needle.”
Several limitations of this study should be acknowl-
edged. This study is based on self-reported behavioural
data obtained from a non-probability sample of street-
involved individuals. Consequently, there is potential for
recall bias, socially desirable reporting, and misclassifica-
tion of exposure variables in this study. Responses to ques-
tions concerning drug use and sexual behaviors may be
influenced by the participant’s knowledge of their HCV
antibody status. In addition, recall problems may exist
with reporting of past traumatic life events. The effect of
memory on our estimates of risk for these factors is diffi-
cult to assess. Additionally, although data were analyzed
using time-dependent variables, we cannot make conclu-
sions regarding temporal sequences between HCV risk
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had never used injection drugs and seroconverted to HCV
positive over the study period was very low (n= 5) we were
therefore unable to examine the risks for HCV incidence
among those participants. Finally, the fact that HCV inci-
dence was lower among participants who had been inject-
ing drugs longer may be demonstrating a survivorship
bias. Therefore, perhaps the most at-risk participants who
had been injecting longest became HCV positive prior to
entering the study. Nevertheless, this study does show
alarming rates of HCV infection early in the injection car-
eer of young Aboriginal people in Vancouver and Prince
George. Despite these limitations, we believe these data
provide important epidemiological information about a
high-risk Aboriginal population that has not been previ-
ously studied.
Conclusions
Results presented in this study suggest that even in the
presence of established harm reduction initiatives in
both Vancouver and Prince George, including fixed and
mobile needle distribution sites, young Aboriginal
people who use drugs are at sustained risk for HCV in-
fection. In addition, the new initiates to injection drug
use were at highest risk, particularly those young people
who were frequently injecting cocaine, sharing rigs and
involved in sex work. In the absence of post-exposure
prophylaxis or an effective HCV vaccine, primary pre-
vention programs must focus on safe injection practices
and reducing the number of people who initiate injec-
tion drug use. Indeed, such high incident rates among
new initiates in this study underscore the importance of
carefully examining the effectiveness of current harm re-
duction initiatives in both rural and urban settings. On
September 30, 2011, the Supreme Court of Canada made
a unanimous decision ordering the federal government
to refrain from its attempts to close Vancouver’s super-
vised injection clinic [29]. It has been speculated that
this landmark decision will provide other Canadian cities
with the authority to open their own safe injection
clinics [30]. Although not statistically significant, the
present study indicated a higher incidence of HCV in
the northern city of Prince George than Vancouver.
Based on the estimates we have obtained in this study,
we speculate similar rates of HCV infection will be
observed in smaller, northern communities throughout
British Columbia. In previous studies, we identified Van-
couver’s safe injection facility as an integral source for
harm reduction programming among Cedar Project par-
ticipants who were already fully entrenched in injection
drug use and HCV positive [31]. Taken together, these
findings underscore the urgent need for expansion of
safe drug use facilities to other locations in BC, includ-
ing the North. Furthermore, current policies andpractices guiding addiction treatment delivery may be
reinforcing the marginalization of street-involved young
Aboriginal people because they fail to address historical
and social injustices that influence resilience, particularly
racial discrimination [32-34]. Treatment delivery for op-
timal adherence among young, HCV positive Aboriginal
people who inject drugs must be individually tailored,
enriched with ancillary psychosocial supports and pro-
vided within a culturally safe setting [7,35]. These find-
ings may be applicable to at-risk young Indigenous
people globally, for example in Australia, where similar
patterns of vulnerabilities have been identified [36]. With
significant increases in resources, acknowledging the
intergenerational trauma related to the residential school
system may be one way that Aboriginal leadership and
addiction specialists and other practitioners can begin to
mitigate the potential impact of the epidemic currently
threatening their communities.
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